Compare BOOT & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOOT | ELVN |
|---|---|---|
| Founded | 1978 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.2B |
| IPO Year | 2014 | 2020 |
| Metric | BOOT | ELVN |
|---|---|---|
| Price | $139.41 | $46.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 17 | 14 |
| Target Price | ★ $180.67 | $74.33 |
| AVG Volume (30 Days) | 832.1K | ★ 1.3M |
| Earning Date | 10-28-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.00 | 3.17 |
| EPS | ★ 4.02 | N/A |
| Revenue | ★ $776,854,000.00 | N/A |
| Revenue This Year | $14.58 | N/A |
| Revenue Next Year | $12.56 | N/A |
| P/E Ratio | $34.89 | ★ N/A |
| Revenue Growth | ★ 14.59 | N/A |
| 52 Week Low | $110.53 | $14.79 |
| 52 Week High | $210.25 | $62.32 |
| Indicator | BOOT | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 57.87 | 49.89 |
| Support Level | $135.35 | $44.18 |
| Resistance Level | $170.63 | $46.96 |
| Average True Range (ATR) | 6.52 | 2.44 |
| MACD | 0.74 | -0.10 |
| Stochastic Oscillator | 51.01 | 34.70 |
Boot Barn Holdings Inc operates specialty retail stores that sell western and work boots and related apparel and accessories. The Company operates retail locations throughout the U.S. and sells its merchandise via the Internet. The Company operates a total of approximately 539 stores in 49 states. All stores operated under the Boot Barn name.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.